Other formats:
BibTeX
LaTeX
RIS
@misc{2327489,
author = {Demlová, Regina and Grodová, Karolína and Maláska, Jan},
address = {Brno},
edition = {NA},
keywords = {REMED; COVID-19; dexamethason; annual safety report; development safety update report; DSUR},
language = {eng},
location = {Brno},
publisher = {MU LF/MŠMT/FN BRNO},
title = {DEVELOPMENT SAFETY UPDATE REPORT REMED 19. 1. 2023 – 23. 2. 2023},
url = {https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005887-70},
year = {2023}
}
TY - GEN
ID - 2327489
AU - Demlová, Regina - Grodová, Karolína - Maláska, Jan
PY - 2023
TI - DEVELOPMENT SAFETY UPDATE REPORT REMED 19. 1. 2023 – 23. 2. 2023
VL - NA
PB - MU LF/MŠMT/FN BRNO
CY - Brno
KW - REMED
KW - COVID-19
KW - dexamethason
KW - annual safety report
KW - development safety update report
KW - DSUR
UR - https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005887-70
N2 - REMED is national, multicentre clinical trial carried out by the University Hospital Brno in cooperation with RI CZECRIN. The primary objective of the study is to test the hypothesis that administration of dexamethasone 20 mg daily is more effective with COVID-19 compared to a daily dose of dexamethasone 6 mg in adult patients with moderate or severe ARDS. During year 2021 was eight newsletters prepared and sent to clinical sites.
ER -
DEMLOVÁ, Regina, Karolína GRODOVÁ and Jan MALÁSKA. \textit{DEVELOPMENT SAFETY UPDATE REPORT REMED 19. 1. 2023 – 23. 2. 2023}. NA. Brno: MU LF/MŠMT/FN BRNO, 2023, 14 pp. NA.
|
